Nov 07, 2024 / 09:00AM GMT
Magnus Corfitzen Ascelia Pharma AB-Chief Executive Officer
Thank you and welcome everyone to the webcast for CF MS Q3 report for 2024 on this call, we will be making forward-looking statements on today's call. We will start with recent key events and then head into our portfolio update before moving to financials and priorities ahead.
After the presentation, we will open up for questions at Elia Pharma. We identify, develop and commercialize novel drugs that address unmet medical needs within rare cancer conditions.
We have two drugs in our pipeline.
Orby Gland is in registration phase as we have successfully completed the pivotal phase three clinical study. Sparkle and we're preparing the ND A submission.
Orby GL has often dropped designation from the FDA and is targeting an addressable market opportunity of $800 million.
Oncol is ready to start phase two in the treatment of gastric cancer based on encouraging results in phase one and a high level of unmet medical need.
Aelia farmer is based in Malur Sweden and we are listed on NASDAQ.com.
Q3 2024 Ascelia Pharma AB Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot